255 related articles for article (PubMed ID: 23522642)
1. Role of plasmapheresis in Waldenström's macroglobulinemia.
Stone MJ; Bogen SA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):238-40. PubMed ID: 23522642
[TBL] [Abstract][Full Text] [Related]
2. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):100-3. PubMed ID: 19362987
[TBL] [Abstract][Full Text] [Related]
3. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Treon SP
Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1157-60. PubMed ID: 18326744
[TBL] [Abstract][Full Text] [Related]
4. Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia.
Stone MJ
Clin Lymphoma Myeloma; 2009 Mar; 9(1):97-9. PubMed ID: 19362986
[TBL] [Abstract][Full Text] [Related]
5. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
6. Plasma exchange in the long-term management of Waldenström's macroglobulinemia.
Buskard NA; Galton DA; Goldman JM; Kohner EM; Grindle CF; Newman DL; Twinn KW; Lowenthal RM
Can Med Assoc J; 1977 Jul; 117(2):135-7. PubMed ID: 406031
[TBL] [Abstract][Full Text] [Related]
7. [Alleviation of ocular complications of the hyperviscosity syndrome in Waldenström's macroglobulinemia using plasma exchange].
Malecaze F; Mathis A; Gonzales C; Lloveras JJ; Goudable C; Arlet P; Bec P
J Fr Ophtalmol; 1986; 9(5):367-71. PubMed ID: 3100607
[TBL] [Abstract][Full Text] [Related]
8. [Hyperviscosity syndrome].
Dumas G; Merceron S; Zafrani L; Canet E; Lemiale V; Kouatchet A; Azoulay E
Rev Med Interne; 2015 Sep; 36(9):588-95. PubMed ID: 25778852
[TBL] [Abstract][Full Text] [Related]
9. Clinical and rheological studies in a patient with hyperviscosity syndrome due to Waldenström's macroglobulinemia.
Somer T; Ditzel J
Bibl Haematol; 1981; (47):242-6. PubMed ID: 6802129
[No Abstract] [Full Text] [Related]
10. Bilateral, persistent serous macular detachments with Waldenström's macroglobulinemia.
Pilon AF; Rhee PS; Messner LV
Optom Vis Sci; 2005 Jul; 82(7):573-8. PubMed ID: 16044069
[TBL] [Abstract][Full Text] [Related]
11. The use of emergency apheresis in the management of plasma cell disorders.
Kalayoglu-Besisik S
Transfus Apher Sci; 2018 Feb; 57(1):35-39. PubMed ID: 29477943
[TBL] [Abstract][Full Text] [Related]
12. [Waldenström's macroglobulinemia: clinical aspects, diagnosis and therapy].
Baldus M; Brass H
Med Klin (Munich); 1992 Aug; 87(8):434-6. PubMed ID: 1406477
[No Abstract] [Full Text] [Related]
13. Hyperviscosity syndrome in Waldenström's macroglobulinemia.
Krol TC; Wood WS
Am Fam Physician; 1981 Aug; 24(2):187-9. PubMed ID: 6789661
[No Abstract] [Full Text] [Related]
14. [Effect of intensive plasmapheresis on the "syndrome of increased viscosity" and blood coagulation system in Waldenstrom's macroglobulinemia].
Mokeeva RA; Zhuravlev VS
Probl Gematol Pereliv Krovi; 1969 Mar; 14(3):8-16. PubMed ID: 4981700
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
Ito K; Kawasaki T; Hirano K; Sekiguchi N
Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
[TBL] [Abstract][Full Text] [Related]
16. Waldenström's macroglobulinemia: treatment approaches for newly diagnosed and relapsed disease.
Hodge LS; Ansell SM
Transfus Apher Sci; 2013 Aug; 49(1):19-23. PubMed ID: 23773867
[TBL] [Abstract][Full Text] [Related]
17. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
18. Waldenstrom's macrogloblinaemia: modified plasmapheresis as treatment option in a Nigeria setting.
Abjah UM; Aken'Ova YA; Ocheni S
Niger J Med; 2002; 11(4):190-2. PubMed ID: 12955999
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
20. Histidine based adsorbents for selective removal of monoclonal immunoglobulin IgM antibodies from Waldenstrom's macroglobulinemia patient sera: a preliminary study.
Srour M; Kassab I; Matta H; Elkak A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Aug; 932():1-5. PubMed ID: 23811496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
